15 May 2002
Hepatitis B vaccine immunogenicity in patients with chronic HCV infection atone year follow-up: the effect of interferon-alpha therapy.
Sławomir Chlabicz, Anna Grzeszczuk, Tadeusz Wojciech ŁapińskiMed Sci Monit 2002; 8(5): CR379-383 :: ID: 420833
Abstract
BACKGROUND: Patients with chronic hepatitis C are at risk of additionalliver damage when infected with other hepatotropic viruses, and should be vaccinated against HAV andHBV. However, the optimal dose and schedule are still being debated. In this study we assessed hepatitisB vaccine immunogenicity in patients with chronic hepatitis C at one-year follow-up. The effect of interferonalpha treatment on vaccine safety and anti-HBs response was also evaluated. MATERIAL/METHODS: 48 hepatitisC patients were enrolled, of whom 12 were on interferon treatment. Recombinant HBV vaccine was administeredon a 0-1-6 month schedule, and anti-HBs titers were measured at months 1, 2, 7, and 18. RESULTS: Theoverall seroprotection rate at month 7 was 72.9% in hepatitis C patients, compared to 90.9% in the controls.Subjects with chronic hepatitis C had significantly lower percentages of good responders: 50% versus90.9%. At month 18, only 34.1% of the HCV patients had seroprotective titers of anti-HBs, compared to90% in the control group. At all study points there were no significant differences in seroconversionrates and seroprotection rates between subgroups of hepatitis C patients receiving interferon or thosewithout antiviral treatment. CONCLUSIONS: Hepatitis C is associated with decreased HBV vaccine response.We suggest that postvaccination anti-HBs testing should be performed in all hepatitis C patients, andadditional vaccine doses should be provided to those without protection. Alternatively, higher dosesof vaccine (40 Kg) may be considered. Treatment with interferon was safe and well tolerated.
Keywords: Hepacivirus, Hepatitis B Antibodies, Hepatitis B Vaccines, Hepatitis C, Hepatitis C Antibodies, Interferon-alpha, Interferons, Liver, Recombinant Proteins, Time Factors
Editorial
01 November 2024 : Editorial
Editorial: Artificial Intelligence (AI), Digital Image Analysis, and the Future of Cancer Diagnosis and PrognosisDOI: 10.12659/MSM.947038
Med Sci Monit 2024; 30:e947038
In Press
Clinical Research
Clinical Outcomes of Talus Bone Marrow Edema: Comparing Plaster Cast, Crutches, and Walking Boot TreatmentsMed Sci Monit In Press; DOI: 10.12659/MSM.946072
Review article
Comprehensive Insights into Arecoline Hydrobromide: Pharmacology, Toxicity, and PharmacokineticsMed Sci Monit In Press; DOI: 10.12659/MSM.945582
Clinical Research
Iliac Periosteal Bone Autografting vs Talus Non-Weight-Bearing Surgery in Hepple V Talus Osteochondral Inju...Med Sci Monit In Press; DOI: 10.12659/MSM.944912
Clinical Research
Impact of Different Orthodontic Appliances on Mandibular Condyle, Anterior Region of Mandibular, and Maxill...Med Sci Monit In Press; DOI: 10.12659/MSM.946265
Most Viewed Current Articles
17 Jan 2024 : Review article 6,335,406
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research 1,908,931
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 695,409
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
07 Jan 2022 : Meta-Analysis 260,542
Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...DOI :10.12659/MSM.935074
Med Sci Monit 2022; 28:e935074